There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the often conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients. The industry faces a sustained increase in the cost of healthcare and an ever-increasing range of expensive drugs and technologies available as potential therapies.
Clearly, difficult choices need to be made by payers and HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available. In terms of innovative agreements, more manufacturers, in more countries, are proposing risk-sharing and value-based schemes more often.
NextLevel Pharma has organized a unique meeting that will be focused purely on risk-sharing and value-based pricing schemes and will provide experts theories and practical case studies of successful models.
Understand the opportunities, obstacles and challenges in designing and implementing innovative agreements. Find out when risk-sharing & value-based agreements are required and how they can be designed to satisfy all stakeholders to gain market access. Understand whether or not the turbulent macroeconomic environment will increase payer motivation for flexible agreements. Obtain the best and most focused picture of risk-sharing and value-based pricing models today. Learn how drug effectiveness is being demonstrated in different regions. Understand the best ways to communicate value and achieve maximum patient and market access. Hear the perspectives of all stakeholder groups: Payers, regulators, insurers, health economists and the pharmaceutical industry. Discover how payers are evaluating conditional reimbursement agreements.
Who should attend?
To request the full agenda please follow the link:
2nd Annual Pharmaceutical Risk-Sharing & Value-Based Pricing & Reimbursement Models
For Booking Information contact:
Tel: +421 232 660 382
Fax: +421 232 660 397